A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index

Rovesti, Giulia; Leone, Francesco; Brandi, Giovanni; Cesario, S.; Scartozzi, Mario; Niger, Monica; Yoo, Changhoon; Filippi, Roberto; Casagrande, Mariaelena; Silvestris, Nicola; Santini, Daniele; Faloppi, Luca; Palloni, Andrea; Bernardini, Laura; Cho, Hyungwoo; Lai, Eleonora; Fenocchio, Elisabetta; Pircher, Chiara; Iacono, Donatella; Lorenzo, Stefania De; Sperti, Elisa; Massa, Valentina; Braud, Filippo de; Jeong, Jae Ho; Aprile, Giuseppe; Burgio, Valentina; Cascinu, Stefano; Casadei-Gardini, Andrea

doi:10.1007/s12029-021-00649-3

Cited by 1 publication

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms [19][20][21] test reactivity), and for this reason, it was not easy to apply in clinical practice. Subsequently, Onodera simplified it as we use it today, making it an easily accessible tool for the clinician on a daily basis.…”

Section: Introductionmentioning

confidence: 99%

“…Subsequently, Onodera simplified it as we use it today, making it an easily accessible tool for the clinician on a daily basis. The prognostic value of PNI is known in patients receiving immunotherapy for various malignancies, such as non-small cell lung cancers, head and neck cancers, biliary tract cancers, and others [20][21][22][23][24][25]. Regarding HCC, its prognostic role has been shown in patients treated with sorafenib and lenvatinib, which are currently the other two treatment options available for first-line therapy [12,14,17,18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Rimini¹,

Persano²,

Tada³

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. Methods: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). Results: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p < 0.01) and progression-free survival (PFS) (8.7 vs. 5.8 months, HR 0.63, p < 0.01) compared to patients with low PNI. At the multivariate analysis, high versus low PNI resulted as an independent prognostic factor for OS (HR 0.49 , p < 0.01) and PFS (HR 0.82, p = 0.01). There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). Conclusion: PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Rimini¹,

Persano²,

Tada³

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index

Abstract: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Cited by 1 publication

References 37 publications

Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Contact Info

Product

Resources

About